Zeta MyoD1 Antibody. Zeta’s recombinant rabbit antibody recognizes MyoD1, one of the MyoD family of myogenic helix-loop-helix transcription factors, which combined with myogenin, plays a role in coordinating the myogenic differentiation pathway from the determination of mesodermal precursors into myoblasts, the differentiation of myoblasts into myotubes, and finally the maturation of myotubes into skeletal myofibers. Normal mature skeletal muscle does not express MyoD1 protein. MyoD1 is expressed in myoblasts before differentiation while myogenin has post-differentiation functions. The MyoD1 antibody immunostaining identifies cells committed to myogenesis in their earliest phase, and thus, it is a better biomarker for less differentiated Rhabdomyosarcomas (RMS). RMS are the most frequent malignant soft tissue neoplasms of childhood. While better differentiated RMS have cross-striations or rhabdomyoblasts that allow for a confident morphologic diagnosis, less differentiated RMS resemble other small blue round-cell tumors. Studies suggest, the MyoD1 antibody may be used together with Myogenin and Desmin antibodies as a panel of markers since any RMS is virtually never negative for all three markers simultaneously.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.